PMID- 16419072
OWN - NLM
STAT- MEDLINE
DCOM- 20060328
LR  - 20220331
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 106
IP  - 4
DP  - 2006 Feb 15
TI  - Evaluation of complete disease remission in acute myeloid leukemia: a prospective 
      study based on cytomorphology, interphase fluorescence in situ hybridization, and 
      immunophenotyping during follow-up in patients with acute myeloid leukemia.
PG  - 839-47
AB  - BACKGROUND: Different diagnostic methods add information to define complete 
      remission (CR) in patients with acute myeloid leukemia (AML). The detection of 
      minimal residual disease (MRD) for predicting prognosis and for therapeutic 
      planning still are under discussion. METHODS: The authors studied 216 patients 
      with AML at the time of initial diagnosis and during follow-up and correlated 
      cytomorphology, interphase fluorescence in situ hybridization (FISH), and flow 
      cytometry results to evaluate response status. They further tested the prognostic 
      impact of those results, especially in patients who achieved a morphologic CR. 
      RESULTS: Interphase FISH was found to be correlated significantly with the 
      clinical course at the time of complete cytomorphologic remission and was more 
      reliable than morphology for defining CR. Furthermore, interphase FISH was 
      correlated with immunophenotyping results at all times during follow-up. 
      CONCLUSIONS: The current results indicated that interphase FISH may be used as a 
      valid MRD parameter in patients with AML. Multiparameter immunophenotyping for 
      MRD also was correlated strongly with the clinical course, and the authors 
      suggest integrating such immunophenotyping into the routine diagnostic panel at 
      the time of diagnosis and during the clinical course in patients with AML.
CI  - Copyright 2006 American Cancer Society.
FAU - Bacher, Ulrike
AU  - Bacher U
AD  - Laboratory for Leukemia Diagnostics, Department for Internal Medicine III, 
      Klinikum Grosshadern, Ludwig-Maximilians University, Munich, Germany. 
      ulrike.bacher@med.uni-muenchen.de
FAU - Kern, Wolfgang
AU  - Kern W
FAU - Schoch, Claudia
AU  - Schoch C
FAU - Schnittger, Susanne
AU  - Schnittger S
FAU - Hiddemann, Wolfgang
AU  - Hiddemann W
FAU - Haferlach, Torsten
AU  - Haferlach T
LA  - eng
PT  - Journal Article
PT  - Validation Study
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
SB  - IM
MH  - Acute Disease
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - Flow Cytometry
MH  - Humans
MH  - Immunophenotyping
MH  - *In Situ Hybridization, Fluorescence
MH  - Interphase
MH  - Leukemia, Myeloid/*genetics/immunology/*pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm, Residual
MH  - Prognosis
MH  - Prospective Studies
MH  - Sensitivity and Specificity
EDAT- 2006/01/19 09:00
MHDA- 2006/03/29 09:00
CRDT- 2006/01/19 09:00
PHST- 2006/01/19 09:00 [pubmed]
PHST- 2006/03/29 09:00 [medline]
PHST- 2006/01/19 09:00 [entrez]
AID - 10.1002/cncr.21665 [doi]
PST - ppublish
SO  - Cancer. 2006 Feb 15;106(4):839-47. doi: 10.1002/cncr.21665.